lunedì, 10 agosto 2026

Notizie AIOM – anno XV n. 644

26 Settembre 2017

MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2− Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy

MONARCH 2 (ClinicalTrials.gov identifier: NCT02107703) compared the efficacy and safety of abemaciclib, a selective cyclin-dependent kinase 4 and 6 inhibitor, plus fulvestrant with fulvestrant alone in patients with advanced breast cancer (ABC). MONARCH 2 was a global, double-blind, ...
Leggi tutto

26 Settembre 2017

Through the ASCO Lens: A Perspective on the Present and Future of Oncology

September 23, 2017 - The clinical oncology community, along with patients, families, pharmaceutical companies, investors, and third-party payers, eagerly awaits the plenary session presentations at the American Society of Clinical Oncology (ASCO) annual meetings as representing ...
Leggi tutto

26 Settembre 2017

FDA Approves Nivolumab for Hepatocellular Carcinoma

September 22, 2017 - The FDA has granted an accelerated approval to nivolumab for the treatment of patients with hepatocellular carcinoma (HCC) following prior sorafenib, regardless of PD-L1 status. The approval is based on 154 patients enrolled in the phase I/II CheckMate-040 ...
Leggi tutto

25 Settembre 2017

FDA Approves Pembrolizumab for PD-L1+ Gastric Cancer

September 22, 2017 - The FDA has approved pembrolizumab for the treatment of patients with PD-L1–positive recurrent or advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma who have received 2 or more lines of chemotherapy, including fluoropyrimidine- ...
Leggi tutto

22 Settembre 2017

Avelumab Approved in Europe for Merkel Cell Carcinoma

September 21, 2017 - The European Commission (EC) has approved avelumab for the treatment of patients with metastatic Merkel cell carcinoma, according to Merck KGaA and Pfizer, the co-developers of the PD-L1 inhibitor. Avelumab is approved for this indication in all 28 EU ...
Leggi tutto

22 Settembre 2017

22 settembre 2017 – AIFA: vaccini influenzali per la stagione 2017-2018

22 Settembre 2017

21 settembre 2017 – Comunicazione su apertura piattaforma Pay-Back 5% – anno 2017

22 Settembre 2017

Randomized Phase III Trial of Adjuvant Pazopanib Versus Placebo After Nephrectomy in Patients With Localized or Locally Advanced Renal Cell Carcinoma

This phase III trial evaluated the efficacy and safety of pazopanib versus placebo in patients with locally advanced renal cell carcinoma (RCC) at high risk for relapse after nephrectomy. A total of 1,538 patients with resected pT2 (high grade) or ≥ pT3, including ...
Leggi tutto

21 Settembre 2017

Lo screening può salvarti la vita!

Cittadinanzattiva ha lanciato una campagna informativa digital sui principali social network, con hashtag #nonaspettare, di supporto al programma nazionale di screening per il cancro alla mammella, al colon retto e alla cervice uterina. Obiettivo è quello di raggiungere ...
Leggi tutto

21 Settembre 2017

Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer

Adjuvant therapy for intermediate-risk and high-risk localized prostate cancer decreases the number of deaths from this disease. Surrogates for overall survival (OS) could expedite the evaluation of new adjuvant therapies. By June 2013, 102 completed or ongoing randomized ...
Leggi tutto